Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| BCMA | >95% | Plasma-cell surface expression | Wikipedia |
| CD38 | >95% | Plasma-cell surface expression | Wikipedia |
| GPRC5D Expression correlates with high risk | 60-80% | High expression by IHC/RNA | Wikipedia |
| Interleukin-6 and IL-6 receptor Bataille 1989 (J Clin Invest); 37% at diagnosis, 13% in stable disease, 60% in fulminating disease, 100% of 11 plasma cell leukaemias and 3% of MGUS/smouldering myeloma | 35% | Detectable serum IL-6 by bioassay in 85 patients with overt multiple myeloma | doi.org |
| Cereblon (CRBN) | nearly all% | Cereblon expression at diagnosis; required for lenalidomide and pomalidomide activity, lost in a minority of refractory disease | doi.org |
| SLAMF7 (CS1) | over 95% | CS1 (SLAMF7) expression on myeloma cells | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
6 cell lines, 1 mouse models and 1 repositories are listed for this cancer. See them →